Marc Thibonnier, M.D., M.Sc.
Dr. Thibonnier is Founder, President, CEO, and member of the Board of Directors at AptamiR. He led a successful career in academic medicine, followed by ten years of leadership in drug development at Bayer, BMS and GSK, overseeing cardiovascular and metabolic drug development from candidate selection to regulatory approval. Dr. Thibonnier earned an M.D. at the Université Pierre et Marie Curie and a M.Sc. at the University of California, San Francisco. He currently holds an appointment as Clinical Professor of Medicine at Stanford University.
Ross Garrett, Ph.D.
Dr. Garrett is Chief Operating Officer / Chief Scientific Officer at AptamiR Therapeutics. Following an accomplished academic career at the University of Adelaide and the University of Texas he held senior positions at Tutume Consulting, Zimmer Biomet, Surgacoll, Elk Biologics and OsteoScreen overseeing drug-device R&D development and operations. Dr Garrett has a PhD in Pathology, MSc in Physiology, BSc in Biochemistry and Organic Chemistry from the University of Adelaide, a degree in Medical Technology from Uni of South Australia and a postgraduate fellowship in Endocrinology at the University of Texas Health Science Center. He currently holds an appointment as Associate Professor at University of Texas.